Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Citius Pharmaceuticals Inc CTXR
$0.50
▼ -4.71%
($-0.02)
🔥 High Short Interest
Open
$0.52
Prev Close
$0.53
Day Range
$0.50 – $0.54
52W Range
$0.37 – $1.54
Market Cap
$14.45M
Beta
1.05
EPS (TTM)
$-2.13
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-08-03 |
| Shares Out. | 27,450,000 |
| Website | citiuspharma.com/ ↗ |
| Phone | 19089676677 |
| Employees | 23 |
| Revenue | $1.5M |
| Gross Profit | $1.0M |
| Net Income | -$11.9M |
| Free Cash Flow | -$34.9M |
| Total Assets | $142.3M |
| Total Liabilities | $66.3M |
| Equity | $75.9M |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Citius Pharmaceuticals Inc is a publicly traded company under the ticker symbol CTXR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-11-01)